PMN Stock Summary and Trading Ideas (Promis Neurosciences - Common Shares | NASDAQ:PMN)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Promis Neurosciences - Common Shares trades on the NASDAQ stock market under the symbol PMN.

As of November 13, 2026, PMN stock price declined to $3.29 with 152,047 million shares trading.

PMN has a beta of -0.66, meaning it tends to be less sensitive to market movements. PMN has a correlation of 0.00 to the broad based SPY ETF.

PMN has a market cap of $29.50 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, PMN traded as high as $77.50 and as low as $2.78.

PMN has underperformed the market in the last year with a price return of -66.3% while the SPY ETF gained +13.4%. PMN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -77.8% and -0.6%, respectively, while the SPY returned -2.8% and -0.2%, respectively.

PMN support price is $3.10 and resistance is $3.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PMN shares will trade within this expected range on the day.